Replimune Group (NASDAQ:REPL) reported fiscal Q1 2026 financial results and provided updates on its oncolytic immunotherapy pipeline. The company received a Complete Response Letter (CRL) from the FDA for RP1 BLA in advanced melanoma on July 22, 2025. Key financial metrics include cash position of $403.3M, increased R&D expenses of $57.8M (vs $43.0M YoY), and a net loss of $86.7M (vs $53.8M YoY).
Multiple clinical trials are progressing, including the Phase 3 IGNYTE-3 trial for RP1 in melanoma, ARTACUS trial showing 34.6% response rate in transplant patients, and the Phase 2/3 REVEAL trial for RP2 in uveal melanoma. The company expects its current cash to fund operations into Q4 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.